Zoetis Inc Class A (ZTS)
Industry Drug Manufacturers - Specialty & Generic
This stock can be held in an Investment ISA and an Investment Account
Sell
$79.25
Buy
$80.35
$ (+%)
Prices updated at 30 Oct 2026, 23:58 EDT
| Prices minimum 15 mins delay
Prices in USD
Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns roughly 30% of total revenue from production animals (cattle, pigs, poultry, and so on) and nearly 70% from companion animal (dog ...
Important documents: Please ensure that you have read the Pre-sale Illustrations document & Doing Business with Fidelity document (incorporating the Fidelity Client Terms) and
- Key stats
- Price
- Fair value
- Dividends
- News
- Financials
- Valuation
- Profile
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Chairman
Mr. Michael B. McCallister
CEO
Ms. Kristin C. Peck
Most recent earnings
31 Dec 2025
Fiscal year end
31 Dec 2025
Employees
14,500
Head office
10 Sylvan Way
Parsippany
United States
07054
Key personnel
Owner name | Salary |
|---|---|
Mr. James K. Saccaro Executive Vice President, Chief Financial Officer and Chief Operating Officer | - |
Ms. Iris Knobloch Director | - |
Mr. Gregory Norden Independent Director | - |
Mr. Michael B. McCallister Chairman of the Board | - |
Mr. Paul M. Bisaro Independent Director | - |
Mr. Frank A. D’Amelio Independent Director | - |
Mr. Sanjay Khosla Independent Director | - |
Ms. Kristin C. Peck Director and Chief Executive Officer | 1.35m |
Mr. Gavin D.K. Hattersley Independent Director | - |
Ms. Stephanie Tilenius Director | - |
Ms. Roxanne Lagano Executive Vice President, General Counsel and Corporate Secretary | 0.70m |
Dr. Willie M. Reed, PhD Independent Director | - |
Ms. Antoinette R. Leatherberry Independent Director | - |
Ms. Julie Fuller Executive Vice President, Global Operations and Chief Human Resources Officer | - |
Ms. Jeannette Ferran Astorga Executive Vice President, Corporate Affairs and Chief Sustainability Officer | - |
Ms. Vanessa Broadhurst Independent Director | - |
Mr. Jamie Brannan Executive Vice President and Chief Commercial Officer | 0.72m |
Ms. Rimma Driscoll Executive Vice President and Head of Global Strategy, Commercial and Business Development and Global BioDevices | - |
Mr. Nick Ashton Executive Vice President and President, Global Manufacturing and Supply | - |
Mr. Keith Sarbaugh Executive Vice President, Chief Digital Officer and Chief Technology Officer | - |
Mr. Mark Stetter Independent Director | - |
Dr. Kevin Esch Executive Vice President and President, Research and Development | - |
Top 5 shareholders
Owner name | No. of shares |
|---|---|
| BlackRock Inc | 35,584,312 |
| Vanguard Group Inc | 31,391,210 |
| Vanguard Capital Management, LLC | 26,072,846 |
| Vanguard Portfolio Management, LLC | 23,967,400 |
| Vanguard | 23,245,276 |
Director dealings
Date | Action |
|---|---|
| 01 Dec 2025 | - |
| 10 Oct 2025 | - |
| 10 Oct 2025 | - |
| 10 Oct 2025 | - |
| 10 Oct 2025 | - |
| 10 Oct 2025 | - |
| 10 Oct 2025 | - |
| 10 Oct 2025 | - |
| 30 Sep 2025 | - |
| 30 Sep 2025 | - |
| 30 Sep 2025 | - |
| 15 Sep 2025 | - |
| 25 Jul 2025 | - |
| 25 Jul 2025 | - |
| 25 Jul 2025 | - |
| 11 Jul 2025 | - |
| 11 Jul 2025 | - |
| 11 Jul 2025 | - |
| 11 Jul 2025 | - |
| 11 Jul 2025 | - |
Please note that past performance is not a reliable indicator of future returns.
